Atea Pharmaceuticals (AVIR) Enterprise Value (2020 - 2022)
Historic Enterprise Value for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q3 2022 value amounting to -$665.0 million.
- Atea Pharmaceuticals' Enterprise Value rose 2080.43% to -$665.0 million in Q3 2022 from the same period last year, while for Sep 2022 it was -$665.0 million, marking a year-over-year increase of 2080.43%. This contributed to the annual value of -$764.4 million for FY2021, which is 1008.59% up from last year.
- According to the latest figures from Q3 2022, Atea Pharmaceuticals' Enterprise Value is -$665.0 million, which was up 2080.43% from -$684.5 million recorded in Q2 2022.
- In the past 5 years, Atea Pharmaceuticals' Enterprise Value registered a high of -$17.1 million during Q1 2020, and its lowest value of -$850.1 million during Q4 2020.
- In the last 3 years, Atea Pharmaceuticals' Enterprise Value had a median value of -$705.5 million in 2022 and averaged -$581.6 million.
- In the last 5 years, Atea Pharmaceuticals' Enterprise Value plummeted by 476237.24% in 2021 and then soared by 2080.43% in 2022.
- Quarter analysis of 3 years shows Atea Pharmaceuticals' Enterprise Value stood at -$850.1 million in 2020, then grew by 10.09% to -$764.4 million in 2021, then grew by 13.0% to -$665.0 million in 2022.
- Its Enterprise Value was -$665.0 million in Q3 2022, compared to -$684.5 million in Q2 2022 and -$705.5 million in Q1 2022.